Figure 5.
![Figure 5. CC-5013 phase 3 trial for advanced and refractory myeloma. (A) Dosing schedule. (B) Kinetics of response according to dosing schedule. M-protein responses were significantly higher with the 25 mg than with the 50 mg CC-5013 dose, although total doses per cycle were identical (500 mg). (C) Grade greater than 2 thrombocytopenia (< 50 000/μL[< 50 × 109/L]) was significantly more frequent and of earlier onset when platelet levels before CC-5013 were less than 100 000/μL (100 × 109/L).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/103/1/10.1182_blood-2003-04-1045/6/h80145469005.jpeg?Expires=1735831278&Signature=xy2wlmCr9ntSfToMr1My8hoAno~iSfMZQp5IDN4iJBqmxi60r61QWuwyPRN3QXYhg~BwIX9K9JOn6HwOAn5MZWhpGAHT-jAD08HugneaX-Oa19-qlY3hmOQUZmbczDqslvnvKaW3wZsd7LNn-n-DDMbeZ4Gb1MWMdgLWRsBgzb0UBy2ijF7NHc9KWYB5hYwJhkZt5bmqFnHgxCMtxHGsWkwfRi7B89GxGpvdo-a~~nMnUurQIo~GGKO0kD~QKh0huDJFfcJ-O2TGnCvB~mqjfmiHTDStLvSGst-81O0mhkg4~sI9iTLHj7lRSZVNV4~4qa-C2lHcUmvNIx25Vhpwpw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
CC-5013 phase 3 trial for advanced and refractory myeloma. (A) Dosing schedule. (B) Kinetics of response according to dosing schedule. M-protein responses were significantly higher with the 25 mg than with the 50 mg CC-5013 dose, although total doses per cycle were identical (500 mg). (C) Grade greater than 2 thrombocytopenia (< 50 000/μL[< 50 × 109/L]) was significantly more frequent and of earlier onset when platelet levels before CC-5013 were less than 100 000/μL (100 × 109/L).
